A BuiltForAI Property
Live data · NADAC + Part D CY24 · reviewed daily

Dextran 40 (LMD in Dextrose)

Plasma Volume Expander class · 0 generic manufacturers · 0 ANDAs filed at FDA.

First FDA approval2005-08-12
Generic availableNo (brand-only)
Shortage statusNone
340B exposureunknown
Last updated
NADAC: weekly (every Wed)Part D Formulary: quarterlyPart D Spend: annual (CY24)Orange Book: weeklyShortages: daily
At a glance · the numbers a plan sponsor wants on screen one
Lowest NADAC
/unit
0 NDCs benchmarked, lowest of all strengths.
Average NADAC
Across all dosage forms in distribution.
Highest NADAC
Range is tight.
Plans with PA
0 / 329
Zero PA friction — switching is purely formulary.

Questions a plan sponsor actually asks.

FAQPage schema9 entries indexed · 4 visible
What is Dextran 40 used for?

Dextran 40 is a Plasma Volume Expander medication tracked in Medicare Part D.

Is there a generic for Dextran 40?

No. Dextran 40 is brand-only with no generic equivalents currently in market.

How much does my plan pay for Dextran 40?

NADAC pricing data not currently available for this drug.

Is Dextran 40 on the FDA shortage list?

No. Dextran 40 is not currently on the FDA Drug Shortage Database.

5 additional drug-specific questions are indexed in the page's FAQPage schema for search engines and LLM crawlers, beyond what renders visually above. View page source for the complete JSON-LD.

Same class. Different math.

Plasma Volume Expander2 alternatives in D1
01
6% Hetastarch In
Plasma Volume Expander
Lowest NADAC
0Generic mfrs
CY24 Part D spend
Compare →
02
Hetastarch
Brand: Hextend
Lowest NADAC
0Generic mfrs
CY24 Part D spend
Compare →

Sources · every number above traces back.

Last refresh30 May 2026

Drug identity, dosage forms, brand names: openFDA NDC Directory · First approval, ANDA history: FDA Orange Book · NADAC unit costs: CMS NADAC weekly file · Formulary tier and PA placement: CMS Part D Formulary file (329 plans) · Annualized spend, claims, beneficiaries: CMS Part D Spending Dashboard · Shortage status: FDA Drug Shortage Database · 340B exposure: HRSA OPAIS. Methodology and reproducibility notes on /methodology.